世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

脂質低下薬市場(薬物クラス:スタチン&コンビネーション、PCSK9阻害剤、胆汁酸封鎖剤、フィブラート、コレステロール吸収阻害剤、その他) - 世界各国の産業分析、サイズ、シェア、成長、トレンド、予測、2023-2031年


Lipid-lowering Drugs Market (Drug Class: Statins & Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

脂質低下薬市場 - レポートの範囲 TMRの調査レポート「世界の脂質低下薬市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や機会も調... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Transparency Market Research
トランスペアレンシーマーケットリサーチ
2023年3月24日 US$5,795
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
240 英語

 

サマリー

脂質低下薬市場 - レポートの範囲
TMRの調査レポート「世界の脂質低下薬市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や機会も調査しています。本レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの期間における世界の脂質低下薬市場の収益を提供します。また、2023年から2031年までの脂質低下薬の世界市場の複合年間成長率(CAGR %)を掲載しています。

本レポートは、広範な調査を経て作成されました。一次調査では、主要なオピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、脂質低下薬市場を把握しました。

また、インターネット上の情報源、政府機関の統計データ、ウェブサイト、業界団体なども二次調査の対象とした。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の脂質低下薬市場の様々な属性を調査しました。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界の脂質低下薬市場における競争ダイナミクスの変化に光を当てています。これらは、既存の市場関係者だけでなく、世界の脂質低下薬市場への参入を検討している企業にとっても、貴重なツールとなります。

本レポートは、世界の脂質低下薬市場の競争環境について掘り下げています。世界の脂質低下薬市場で事業を展開する主要企業が特定され、それぞれの企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の脂質低下薬市場のプレーヤーの属性です。

脂質低下薬の世界市場レポートで回答された主な質問
- 予測期間中、全地域における脂質低下薬の売上/収益はどの程度か?
- 世界の脂質低下薬市場におけるビジネスチャンスは何か?
- 市場における主な促進要因、阻害要因、機会、脅威は何か?
- 予測期間中に最も速いCAGRで拡大する地域市場はどこか?
- 2031年に世界で最も高い収益を上げると予測されるセグメントは?
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントはどこか?
- 世界市場で事業展開している各社の市場ポジションは?

脂質低下薬市場 - 研究目的と研究アプローチ
脂質低下薬の世界市場に関する包括的なレポートは、まず概要から始まり、次に調査範囲と目的について説明しています。本調査の目的、市場で活動する主要ベンダーや流通業者、製品の承認に関する規制シナリオについて詳しく解説しています。

読みやすさを考慮し、本レポートは章立てでまとめられ、各セクションはより小さなものに分割されています。本レポートは、グラフと表が適切に配置された包括的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えかけています。また、過去と予測期間終了時の主要セグメントの市場シェアを比較することも可能です。

本レポートでは、脂質低下薬の世界市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントごとの市場シェアを掲載しています。このような貴重な洞察により、市場関係者は、世界の脂質低下薬市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。

ページTOPに戻る


目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lipid-lowering Drugs Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Lipid-lowering Drugs Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Drug Pipeline Analysis
    5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
    5.3. Regulatory Scenario by Region/globally
    5.4. Patent Analysis
6. Global Lipid-lowering Drugs Market Analysis and Forecast, by Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Drug Class, 2017-2031
        6.3.1. Statins & Combination
        6.3.2. PCSK9 Inhibitors
        6.3.3. Bile Acid Sequestrants
        6.3.4. Fibrates
        6.3.5. Cholesterol Absorption Inhibitors
        6.3.6. Others
    6.4. Market Attractiveness, by Drug Class
7. Global Lipid-lowering Drugs Market Analysis and Forecast, by Indication
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Indication, 2017-2031
        7.3.1. Hypercholesterolemia
        7.3.2. Coronary Artery Disease
        7.3.3. High Triglycerides
    7.4. Market Attractiveness, by Indication
8. Global Lipid-lowering Drugs Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017-2031
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness, by Distribution Channel
9. Global Lipid-lowering Drugs Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness, by Country/Region
10. North America Lipid-lowering Drugs Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Class, 2017-2031
        10.2.1. Statins & Combination
        10.2.2. PCSK9 Inhibitors
        10.2.3. Bile Acid Sequestrants
        10.2.4. Fibrates
        10.2.5. Cholesterol Absorption Inhibitors
        10.2.6. Others
    10.3. Market Value Forecast, by Indication, 2017-2031
        10.3.1. Hypercholesterolemia
        10.3.2. Coronary Artery Disease
        10.3.3. High Triglycerides
    10.4. Market Value Forecast, by Distribution Channel, 2017-2031
        10.4.1. Hospital Pharmacies
        10.4.2. Retail Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country, 2017-2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Drug Class
        10.6.2. By Indication
        10.6.3. By Distribution Channel
        10.6.4. By Country
11. Europe Lipid-lowering Drugs Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Class, 2017-2031
        11.2.1. Statins & Combination
        11.2.2. PCSK9 Inhibitors
        11.2.3. Bile Acid Sequestrants
        11.2.4. Fibrates
        11.2.5. Cholesterol Absorption Inhibitors
        11.2.6. Others
    11.3. Market Value Forecast, by Indication, 2017-2031
        11.3.1. Hypercholesterolemia
        11.3.2. Coronary Artery Disease
        11.3.3. High Triglycerides
    11.4. Market Value Forecast, by Distribution Channel, 2017-2031
        11.4.1. Hospital Pharmacies
        11.4.2. Retail Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Spain
        11.5.5. Italy
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Drug Class
        11.6.2. By Indication
        11.6.3. By Distribution Channel
        11.6.4. By Country/Sub-region
12. Asia Pacific Lipid-lowering Drugs Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Class, 2017-2031
        12.2.1. Statins & Combination
        12.2.2. PCSK9 Inhibitors
        12.2.3. Bile Acid Sequestrants
        12.2.4. Fibrates
        12.2.5. Cholesterol Absorption Inhibitors
        12.2.6. Others
    12.3. Market Value Forecast, by Indication, 2017-2031
        12.3.1. Hypercholesterolemia
        12.3.2. Coronary Artery Disease
        12.3.3. High Triglycerides
    12.4. Market Value Forecast, by Distribution Channel, 2017-2031
        12.4.1. Hospital Pharmacies
        12.4.2. Retail Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Drug Class
        12.6.2. By Indication
        12.6.3. By Distribution Channel
        12.6.4. By Country/Sub-region
13. Latin America Lipid-lowering Drugs Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Class, 2017-2031
        13.2.1. Statins & Combination
        13.2.2. PCSK9 Inhibitors
        13.2.3. Bile Acid Sequestrants
        13.2.4. Fibrates
        13.2.5. Cholesterol Absorption Inhibitors
        13.2.6. Others
    13.3. Market Value Forecast, by Indication, 2017-2031
        13.3.1. Hypercholesterolemia
        13.3.2. Coronary Artery Disease
        13.3.3. High Triglycerides
    13.4. Market Value Forecast, by Distribution Channel, 2017-2031
        13.4.1. Hospital Pharmacies
        13.4.2. Retail Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast By Country/Sub-region, 2017-2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Drug Class
        13.6.2. By Indication
        13.6.3. By Distribution Channel
        13.6.4. By Country/Sub-region
14. Middle East & Africa Lipid-lowering Drugs Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Class, 2017-2031
        14.2.1. Statins & Combination
        14.2.2. PCSK9 Inhibitors
        14.2.3. Bile Acid Sequestrants
        14.2.4. Fibrates
        14.2.5. Cholesterol Absorption Inhibitors
        14.2.6. Others
    14.3. Market Value Forecast, by Indication, 2017-2031
        14.3.1. Hypercholesterolemia
        14.3.2. Coronary Artery Disease
        14.3.3. High Triglycerides
    14.4. Market Value Forecast, by Distribution Channel, 2017-2031
        14.4.1. Hospital Pharmacies
        14.4.2. Retail Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Drug Class
        14.6.2. By Indication
        14.6.3. By Distribution Channel
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (By Tier and Size of companies)
    15.2. Market Share/Ranking Analysis By Company (2022)
    15.3. Company Profiles
        15.3.1. Sanofi
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Strategic Overview
        15.3.2. Pfizer, Inc.
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Strategic Overview
        15.3.3. GlaxoSmithKline plc
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Strategic Overview
        15.3.4. Novartis AG
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Strategic Overview
        15.3.5. Merck & Co., Inc.
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Strategic Overview
        15.3.6. Amgen Inc.
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Strategic Overview
        15.3.7. Takeda Pharmaceutical Company Limited
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Strategic Overview
        15.3.8. Sun Pharmaceutical Industries Ltd.
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Strategic Overview
        15.3.9. AbbVie, Inc.
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Strategic Overview
        15.3.10. Viatris (Mylan N.V.)
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Strategic Overview
        15.3.11. AstraZeneca PLC
            15.3.11.1. Company Overview
            15.3.11.2. Product Portfolio
            15.3.11.3. SWOT Analysis
            15.3.11.4. Strategic Overview
        15.3.12. Dr. Reddy’s Laboratories Ltd.
            15.3.12.1. Company Overview
            15.3.12.2. Product Portfolio
            15.3.12.3. SWOT Analysis
            15.3.12.4. Strategic Overview

ページTOPに戻る



図表リスト

List of Tables

Table 01: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 02: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by 2017‒2031, by Indication

Table 03: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 07: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 08: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 10: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 11: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 12: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 15: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 16: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 18: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 19: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 20: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 23: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 24: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

 

ページTOPに戻る


 

Summary

Lipid-lowering Drugs Market – Scope of Report
TMR’s report on the global lipid-lowering drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global lipid-lowering drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lipid-lowering drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the lipid-lowering drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lipid-lowering drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lipid-lowering drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lipid-lowering drugs market.

The report delves into the competitive landscape of the global lipid-lowering drugs market. Key players operating in the global lipid-lowering drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lipid-lowering drugs market profiled in this report.

Key Questions Answered in Global Lipid-lowering Drugs Market Report
• What is the sales/revenue generated by lipid-lowering drugs across all regions during the forecast period?
• What are the opportunities in the global lipid-lowering drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Lipid-lowering Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global lipid-lowering drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lipid-lowering drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lipid-lowering drugs market.



ページTOPに戻る


Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lipid-lowering Drugs Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Lipid-lowering Drugs Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Drug Pipeline Analysis
    5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
    5.3. Regulatory Scenario by Region/globally
    5.4. Patent Analysis
6. Global Lipid-lowering Drugs Market Analysis and Forecast, by Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Drug Class, 2017-2031
        6.3.1. Statins & Combination
        6.3.2. PCSK9 Inhibitors
        6.3.3. Bile Acid Sequestrants
        6.3.4. Fibrates
        6.3.5. Cholesterol Absorption Inhibitors
        6.3.6. Others
    6.4. Market Attractiveness, by Drug Class
7. Global Lipid-lowering Drugs Market Analysis and Forecast, by Indication
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Indication, 2017-2031
        7.3.1. Hypercholesterolemia
        7.3.2. Coronary Artery Disease
        7.3.3. High Triglycerides
    7.4. Market Attractiveness, by Indication
8. Global Lipid-lowering Drugs Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017-2031
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness, by Distribution Channel
9. Global Lipid-lowering Drugs Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness, by Country/Region
10. North America Lipid-lowering Drugs Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Class, 2017-2031
        10.2.1. Statins & Combination
        10.2.2. PCSK9 Inhibitors
        10.2.3. Bile Acid Sequestrants
        10.2.4. Fibrates
        10.2.5. Cholesterol Absorption Inhibitors
        10.2.6. Others
    10.3. Market Value Forecast, by Indication, 2017-2031
        10.3.1. Hypercholesterolemia
        10.3.2. Coronary Artery Disease
        10.3.3. High Triglycerides
    10.4. Market Value Forecast, by Distribution Channel, 2017-2031
        10.4.1. Hospital Pharmacies
        10.4.2. Retail Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country, 2017-2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Drug Class
        10.6.2. By Indication
        10.6.3. By Distribution Channel
        10.6.4. By Country
11. Europe Lipid-lowering Drugs Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Class, 2017-2031
        11.2.1. Statins & Combination
        11.2.2. PCSK9 Inhibitors
        11.2.3. Bile Acid Sequestrants
        11.2.4. Fibrates
        11.2.5. Cholesterol Absorption Inhibitors
        11.2.6. Others
    11.3. Market Value Forecast, by Indication, 2017-2031
        11.3.1. Hypercholesterolemia
        11.3.2. Coronary Artery Disease
        11.3.3. High Triglycerides
    11.4. Market Value Forecast, by Distribution Channel, 2017-2031
        11.4.1. Hospital Pharmacies
        11.4.2. Retail Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Spain
        11.5.5. Italy
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Drug Class
        11.6.2. By Indication
        11.6.3. By Distribution Channel
        11.6.4. By Country/Sub-region
12. Asia Pacific Lipid-lowering Drugs Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Class, 2017-2031
        12.2.1. Statins & Combination
        12.2.2. PCSK9 Inhibitors
        12.2.3. Bile Acid Sequestrants
        12.2.4. Fibrates
        12.2.5. Cholesterol Absorption Inhibitors
        12.2.6. Others
    12.3. Market Value Forecast, by Indication, 2017-2031
        12.3.1. Hypercholesterolemia
        12.3.2. Coronary Artery Disease
        12.3.3. High Triglycerides
    12.4. Market Value Forecast, by Distribution Channel, 2017-2031
        12.4.1. Hospital Pharmacies
        12.4.2. Retail Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Drug Class
        12.6.2. By Indication
        12.6.3. By Distribution Channel
        12.6.4. By Country/Sub-region
13. Latin America Lipid-lowering Drugs Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Class, 2017-2031
        13.2.1. Statins & Combination
        13.2.2. PCSK9 Inhibitors
        13.2.3. Bile Acid Sequestrants
        13.2.4. Fibrates
        13.2.5. Cholesterol Absorption Inhibitors
        13.2.6. Others
    13.3. Market Value Forecast, by Indication, 2017-2031
        13.3.1. Hypercholesterolemia
        13.3.2. Coronary Artery Disease
        13.3.3. High Triglycerides
    13.4. Market Value Forecast, by Distribution Channel, 2017-2031
        13.4.1. Hospital Pharmacies
        13.4.2. Retail Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast By Country/Sub-region, 2017-2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Drug Class
        13.6.2. By Indication
        13.6.3. By Distribution Channel
        13.6.4. By Country/Sub-region
14. Middle East & Africa Lipid-lowering Drugs Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Class, 2017-2031
        14.2.1. Statins & Combination
        14.2.2. PCSK9 Inhibitors
        14.2.3. Bile Acid Sequestrants
        14.2.4. Fibrates
        14.2.5. Cholesterol Absorption Inhibitors
        14.2.6. Others
    14.3. Market Value Forecast, by Indication, 2017-2031
        14.3.1. Hypercholesterolemia
        14.3.2. Coronary Artery Disease
        14.3.3. High Triglycerides
    14.4. Market Value Forecast, by Distribution Channel, 2017-2031
        14.4.1. Hospital Pharmacies
        14.4.2. Retail Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Drug Class
        14.6.2. By Indication
        14.6.3. By Distribution Channel
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (By Tier and Size of companies)
    15.2. Market Share/Ranking Analysis By Company (2022)
    15.3. Company Profiles
        15.3.1. Sanofi
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Strategic Overview
        15.3.2. Pfizer, Inc.
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Strategic Overview
        15.3.3. GlaxoSmithKline plc
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Strategic Overview
        15.3.4. Novartis AG
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Strategic Overview
        15.3.5. Merck & Co., Inc.
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Strategic Overview
        15.3.6. Amgen Inc.
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Strategic Overview
        15.3.7. Takeda Pharmaceutical Company Limited
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Strategic Overview
        15.3.8. Sun Pharmaceutical Industries Ltd.
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Strategic Overview
        15.3.9. AbbVie, Inc.
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Strategic Overview
        15.3.10. Viatris (Mylan N.V.)
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Strategic Overview
        15.3.11. AstraZeneca PLC
            15.3.11.1. Company Overview
            15.3.11.2. Product Portfolio
            15.3.11.3. SWOT Analysis
            15.3.11.4. Strategic Overview
        15.3.12. Dr. Reddy’s Laboratories Ltd.
            15.3.12.1. Company Overview
            15.3.12.2. Product Portfolio
            15.3.12.3. SWOT Analysis
            15.3.12.4. Strategic Overview

ページTOPに戻る



List of Tables/Graphs

List of Tables

Table 01: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 02: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by 2017‒2031, by Indication

Table 03: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 07: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 08: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 10: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 11: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 12: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 15: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 16: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 18: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 19: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 20: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 23: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 24: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

Transparency Market Research社の製薬分野での最新刊レポート


よくあるご質問


Transparency Market Research社はどのような調査会社ですか?


トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る